Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Division of Immunology, University Children's Hospital Zurich and Clinical Research Center, University of Zurich, Switzerland; Alchemab Therapeutics Ltd, London, United Kingdom.
Int J Parasitol. 2022 Oct;52(11):707-710. doi: 10.1016/j.ijpara.2021.11.008. Epub 2021 Dec 9.
Malaria transmission-blocking vaccines induce antibodies that target Plasmodium in the mosquito vector. We recently reported that Pfs230 vaccine achieves activity superior to Pfs25 in humans. Here, we describe clonal expansion in the variable region of immunoglobulin heavy chains (VH) of antigen-specific single B cells collected from humans immunised with Pfs230D1-EPA or Pfs25-EPA conjugate vaccines formulated in Alhydrogel®. Based on studies of CD27+ memory B cells following Pfs230 vaccination, clonal expansion and somatic hypermutation was seen in four of five subjects. Pfs25 did not induce sufficient CD27+ cells for sorting; based instead on CD19+ Pfs25-reactive B cells, clonal expansion was only seen in two of five subjects. Clonal expansions and mutations in Pfs230-specific single B cells combined with the enhanced activity of Pfs230 antibodies by complement, might justify the outstanding activity of Pfs230D1 as a TBV candidate.
疟疾传播阻断疫苗诱导针对蚊子媒介中疟原虫的抗体。我们最近报道称,Pfs230 疫苗在人类中的效果优于 Pfs25。在此,我们描述了从接种 Pfs230D1-EPA 或 Pfs25-EPA 缀合疫苗的人类免疫原性单 B 细胞中免疫球蛋白重链(VH)可变区的抗原特异性单 B 细胞中克隆扩增。基于 Pfs230 疫苗接种后 CD27+记忆 B 细胞的研究,在五名受试者中的四名中观察到克隆扩增和体细胞超突变。Pfs25 未诱导足够数量的 CD27+细胞进行分选;而是基于 CD19+Pfs25 反应性 B 细胞,仅在五名受试者中的两名中观察到克隆扩增。Pfs230 特异性单 B 细胞的克隆扩增和突变,以及补体增强的 Pfs230 抗体的活性,可能证明 Pfs230D1 作为 TBV 候选物的出色活性是合理的。